D
Davide Ruggero
Researcher at University of California, San Francisco
Publications - 118
Citations - 20361
Davide Ruggero is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Translation (biology) & EIF4E. The author has an hindex of 49, co-authored 111 publications receiving 17167 citations. Previous affiliations of Davide Ruggero include Fox Chase Cancer Center & University of Bologna.
Papers
More filters
Journal ArticleDOI
Kaplan et al. reply
Rosandra N. Kaplan,Rebecca D. Riba,Stergios Zacharoulis,Anna H. Bramley,Loic Vincent,Carla Costa,Daniel D. MacDonald,David K. Jin,Koji Shido,Scott A. Kerns,Zhenping Zhu,Daniel J. Hicklin,Yan Wu,Jeffrey L. Port,Nasser K. Altorki,Elisa Port,Davide Ruggero,Sergey V. Shmelkov,Kristian K. Jensen,Shahin Rafii,David Lyden,Jared Wels +21 more
TL;DR: It is shown that VEGFR1 knockdown in myelomonocytic cells eradicates micro- and macrometastases in a non-amputation/resection tumour model.
Journal ArticleDOI
The major cap-binding protein eIF4E regulates lipid homeostasis and diet-induced obesity.
Crystal S. Conn,Haojun Yang,Harrison J. Tom,Kenji Ikeda,Juan A. Oses-Prieto,Hieu Sy Vu,Yasuo Oguri,Supna Nair,Ryan M. Gill,Shingo Kajimura,Ralph J. DeBerardinis,Alma L. Burlingame,Davide Ruggero +12 more
TL;DR: In this paper, the major cap-binding protein, eIF4E, was shown to have an unexpected function for the major capspin binding protein in high-fat-diet-induced obesity.
Journal ArticleDOI
Early Hematopoietic Progenitors of Dkc1 Hypomorphic Mutant Mice Display Decreased Proliferation Rate and an Impaired Control of Serine/Arginine-Rich Splicing Factor 4 (Srsf4) Translation
Antonio R. Lucena-Araujo,Barbara A. Santana-Lemos,Carol Hassibe Thomé,Germano Aguiar Ferreira,Davide Ruggero,Vitor M. Faça,Eduardo Magalhães Rego +6 more
TL;DR: The in vivo analysis of the proliferation rate of hematopoietic progenitors in Dkc1m mice is described and the proteomic profile of heMatopoietsis and oncogenesis is compared to compare the wild-type controls and no differences were detected in the number of lineage-negative, Sca1-positive, c-kit-negative (LSK−) cells, multipotent precursors (MPP), common myeloid progenitor
Patent
Phosphoribosyl pyrophosphate synthetase 2 (PRPS2) as a therapeutic target in cancer treatment
TL;DR: In this article, the authors present methods of selectively killing a cell, comprising contacting the cell with an agent that inhibits phospho-ribosyl pyrophophosphate synthetase 2 (PRPS2).